Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes.
Hwang J, Likasitwatanakul P, Deshmukh SK, Wu S, Kwon JJ, Toye E, Moline D, Evans MG, Elliott A, Passow R, Luo C, John E, Gandhi N, McKay RR, Heath EI, Nabhan C, Reizine N, Orme JJ, Domingo Domenech JM, Sartor O, Baca SC, Dehm SM, Antonarakis ES.
Hwang J, et al. Among authors: wu s.
Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-3471. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39745364